- Company to Resubmit NDA in Late Second Quarter 2013
- Short-term Clinical Benefit Adequate to Support Approval
- Company to Host Conference Call Today at 9:00 AM ET
Chelsea Therapeutics (CHTP) soared Thursday amid news that Danish pharmaceutical company H. Lundbeck would takeover the company for up to $658 million.
Chelsea CEO Joe Oliveto and his team deserve a lot of credit for cleaning up some messy Northera clinical trials, scoring at the FDA advisory panel, securing the drug's approval and now delivering on the exit strategy that everyone wanted.
Wedbush believed that Chelsea Therapeutics International is an attractive acquisition or partnership target for multiple pharmaceutical companies because of the approval of NortheraThe stock price of ...